Literature DB >> 29907821

New windows open for immunotherapy in lung cancer.

Lizza Hendriks, Benjamin Besse.   

Abstract

Entities:  

Keywords:  Cancer; Immunology; Medical research

Mesh：

Substances：

Year:  2018        PMID： 29907821     DOI： 10.1038/d41586-018-05312-9

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  14 in total

1.  Natural killer cell transcriptional control, subsets, receptors and effector function.

Authors:  Daniel M Altmann
Journal:  Immunology       Date:  2019-02       Impact factor: 7.397

2.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

Authors:  Aurelien Marabelle; Dung T Le; Paolo A Ascierto; Anna Maria Di Giacomo; Ana De Jesus-Acosta; Jean-Pierre Delord; Ravit Geva; Maya Gottfried; Nicolas Penel; Aaron R Hansen; Sarina A Piha-Paul; Toshihiko Doi; Bo Gao; Hyun Cheol Chung; Jose Lopez-Martin; Yung-Jue Bang; Ronnie Shapira Frommer; Manisha Shah; Razi Ghori; Andrew K Joe; Scott K Pruitt; Luis A Diaz
Journal:  J Clin Oncol       Date:  2019-11-04       Impact factor: 44.544

3.  Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study

Authors:  Xue Bai; De-Hua Wu; Si-Cong Ma; Jian Wang; Xin-Ran Tang; Shuai Kang; Qiang John Fu; Chuan-Hui Cao; He-San Luo; Yu-Han Chen; Hong-Bo Zhu; Hong-Hong Yan; Yi-Long Wu; Zhong-Yi Dong
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

Review 4.  Recent Trends in Potential Therapeutic Applications of the Dietary Flavonoid Didymin.

Authors:  Qing Yao; Meng-Ting Lin; Yin-Di Zhu; He-Lin Xu; Ying-Zheng Zhao
Journal:  Molecules       Date:  2018-10-06       Impact factor: 4.411

5.  Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth.

Authors:  Anchalee Rawangkan; Pattama Wongsirisin; Kozue Namiki; Keisuke Iida; Yasuhito Kobayashi; Yoshihiko Shimizu; Hirota Fujiki; Masami Suganuma
Journal:  Molecules       Date:  2018-08-18       Impact factor: 4.411

6.  The difference and relationship of CD4+ and CD8+ tumour infiltrating lymphocytes in lung adenocarcinoma.

Authors:  Chaoting Zhang; Zheming Lu; Hongying Huang
Journal:  Oncotarget       Date:  2019-02-12

7.  Dysbiosis of the Gut Microbiome in Lung Cancer.

Authors:  He Zhuang; Liang Cheng; Yao Wang; Yu-Kun Zhang; Man-Fei Zhao; Gong-Da Liang; Meng-Chun Zhang; Yong-Guo Li; Jing-Bo Zhao; Yi-Na Gao; Yu-Jie Zhou; Shu-Lin Liu
Journal:  Front Cell Infect Microbiol       Date:  2019-04-18       Impact factor: 5.293

8.  Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice.

Authors:  Wenwen Yue; Liang Chen; Luodan Yu; Bangguo Zhou; Haohao Yin; Weiwei Ren; Chang Liu; Lehang Guo; Yifeng Zhang; Liping Sun; Kun Zhang; Huixiong Xu; Yu Chen
Journal:  Nat Commun       Date:  2019-05-02       Impact factor: 14.919

9.  Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.

Authors:  Chih-Hsi Scott Kuo; Chin-Chou Wang; Yu-Chen Huang; Stelios Pavlidis; Chien-Ying Liu; How-Wen Ko; Fu-Tsai Chung; Tin-Yu Lin; Chih-Liang Wang; Yi-Ke Guo; Cheng-Ta Yang
Journal:  Thorac Cancer       Date:  2019-04-05       Impact factor: 3.500

Review 10.  Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer.

Authors:  Wentao Tian; Chenghui Cao; Long Shu; Fang Wu
Journal:  Onco Targets Ther       Date:  2020-11-24       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.